ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 13
- Registration Number
- NCT04477486
- Locations
- 🇯🇵
Duplicate_Okayama University Hospital /ID# 221623, Okayama-shi, Okayama, Japan
🇯🇵NHO Nagoya Medical Center /ID# 221958, Nagoya-shi, Aichi, Japan
🇯🇵Aichi Cancer Center Hospital /ID# 221565, Nagoya-shi, Aichi, Japan
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
- Conditions
- Myelofibrosis (MF)
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT04472598
- Locations
- 🇮🇱
Meir Medical Center /ID# 221374, Kfar Saba, HaMerkaz, Israel
🇮🇱Yitzhak Shamir Medical Center /ID# 222957, Zerifin, HaMerkaz, Israel
🇮🇱The Chaim Sheba Medical Center /ID# 219137, Ramat Gan, Tel-Aviv, Israel
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
- Conditions
- Myelofibrosis (MF)
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 330
- Registration Number
- NCT04468984
- Locations
- 🇦🇹
Medizinische Universitaet Graz /ID# 220919, Graz, Steiermark, Austria
🇦🇹Medizinische Universitaet Wien /ID# 220911, Vienna, Wien, Austria
🇧🇪Cliniques Universitaires UCL Saint-Luc /ID# 224221, Bruxelles, Bruxelles-Capitale, Belgium
A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and Capsules
- Conditions
- EndometriosisUterine Fibrioids
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 584
- Registration Number
- NCT04464187
- Locations
- 🇺🇸
Iqvia /Id# 240918, Durham, North Carolina, United States
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
- Conditions
- Myelofibrosis (MF)
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 21
- Registration Number
- NCT04454658
- Locations
- 🇦🇺
Royal Perth Hospital /ID# 241678, Perth, Western Australia, Australia
🇺🇸The Mount Sinai Hospital /ID# 221549, New York, New York, United States
🇺🇸University of Oklahoma, Stephenson Cancer Center /ID# 224095, Oklahoma City, Oklahoma, United States
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 119
- Registration Number
- NCT04451720
- Locations
- 🇯🇵
St.Luke's International Hospital /ID# 219019, Chuo-ku, Tokyo, Japan
🇯🇵Tokyo Medical University Hospital /ID# 218893, Shinjuku-ku, Tokyo, Japan
🇯🇵Seibo Hospital /ID# 221691, Shinjuku-ku, Tokyo, Japan
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 185
- Registration Number
- NCT04451772
- Locations
- 🇺🇸
Duplicate_AZ Arthritis and Rheumotology Research, PLLC /ID# 227833, Phoenix, Arizona, United States
🇺🇸Duplicate_NYU Langone Health/NYU School of Medicine /ID# 245088, New York, New York, United States
🇨🇳Duplicate_Peking Union Medical College Hospital /ID# 222950, Beijing, Beijing, China
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 186
- Registration Number
- NCT04437433
- Locations
- 🇯🇵
Takanoko Hospital /ID# 232723, Matsuyama-shi, Ehime, Japan
🇯🇵Mito Kyodo General Hospital /ID# 232990, Mito-shi, Ibaraki, Japan
🇯🇵Saitama Neuropsychiatric Institute /Id# 232711, Saitama-shi, Saitama, Japan
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 139
- Registration Number
- NCT04435600
- Locations
- 🇬🇧
Chelsea and Westminster Hospital /ID# 227231, London, Greater London, United Kingdom
🇺🇸UAB Department of Dermatology /ID# 218834, Birmingham, Alabama, United States
🇺🇸First OC Dermatology /ID# 217733, Fountain Valley, California, United States
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
- Conditions
- PsoriasisPsoriatic Arthritis
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3000
- Registration Number
- NCT04433442
- Locations
- 🇰🇷
Dongguk University Ilsan Hospital /ID# 259337, Ilsan, Gyeonggido, Korea, Republic of
🇰🇷Gachon University Gil Medical Center /ID# 262788, Incheon, Gyeonggido, Korea, Republic of
🇰🇷Catholic Kwandong University International St.Mary's Hospital /ID# 262855, Incheon, Gyeonggido, Korea, Republic of